The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The study consists of the two parts, the first one is SHR7390 combined with SHR-1210, the
second one is SHR7390 combined with SHR-1210 and SHR3162. Two parts of the study are
separately to assess the safety and tolerability, to define dose limiting toxicity（DLT) and
maximum tolerated dose (MTD),to evaluate the pharmacokinetics ,to assess the antitumor
activity in patients with advanced solid tumors preliminarily and to recommend reasonable
dosage regimen of SHR7390 for the follow-up clinical trial.